Bloomberg News

Can Fite Poised for Biggest Gain Since November

February 22, 2012

(Corrects share price in second paragraph.)

Feb. 22 (Bloomberg) -- Can Fite Biopharma Ltd. headed for the biggest gain since November after the the U.S. Food and Drug Administration gave its CF102 drug to treat primary liver cancer orphan status.

The shares soared 7.6 percent, the most since Nov. 6, to 0.479 shekels at 1:12 p.m. in Tel Aviv. That gave the company a market value of 125 million shekels ($33 million).

--Editor: Claudia Maedler

To contact the reporter on this story: Gwen Ackerman in Jerusalem at gackerman@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus